Comparing Theravance Biopharma (NASDAQ:TBPH) & Mannatech (NASDAQ:MTEX)

Mannatech (NASDAQ:MTEX) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations.

Institutional & Insider Ownership

13.0% of Mannatech shares are owned by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are owned by institutional investors. 41.5% of Mannatech shares are owned by insiders. Comparatively, 7.7% of Theravance Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

Mannatech has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500. Comparatively, Theravance Biopharma has a beta of 0.17, indicating that its stock price is 83% less volatile than the S&P 500.

Earnings and Valuation

This table compares Mannatech and Theravance Biopharma”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mannatech	$108.04 million	0.10	-$15.21 million	($6.71)	-0.81
Theravance Biopharma	$107.46 million	7.95	$105.89 million	$2.20	7.54

Theravance Biopharma has lower revenue, but higher earnings than Mannatech. Mannatech is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Mannatech and Theravance Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mannatech	-11.97%	-2,383.34%	-40.24%
Theravance Biopharma	104.34%	18.84%	10.94%

Analyst Ratings

This is a summary of current ratings and target prices for Mannatech and Theravance Biopharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mannatech	1	0	0	0	1.00
Theravance Biopharma	0	5	2	0	2.29

Theravance Biopharma has a consensus price target of $21.40, indicating a potential upside of 29.07%. Given Theravance Biopharma’s stronger consensus rating and higher probable upside, analysts plainly believe Theravance Biopharma is more favorable than Mannatech.

Summary

Theravance Biopharma beats Mannatech on 11 of the 14 factors compared between the two stocks.

About Mannatech

Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.

About Theravance Biopharma

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs.
Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY.
For more information, please visit www.theravance.com.